RETRACTED: PS 124 - Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (Psc) in Individuals with Inflammatory Bowel Disease
- DOI
- 10.1016/s0168-8278(16)01707-4
- Published
- 2016
- Container
- Journal of Hepatology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
serious concern Score 29/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- serious concernRetraction Watch retraction: 1 retraction notice matched this DOI.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/s0168-8278-16-01707-4,
title = {RETRACTED: PS 124 - Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (Psc) in Individuals with Inflammatory Bowel Disease},
author = {B. Eksteen and J. Heatherington and J. Oshiomogo and R. Panaccione and G. Kaplan and S. Ghosh},
year = {2016},
journal = {Journal of Hepatology},
doi = {10.1016/s0168-8278(16)01707-4},
url = {https://doi.org/10.1016/s0168-8278(16)01707-4}
}RIS
TY - JOUR TI - RETRACTED: PS 124 - Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (Psc) in Individuals with Inflammatory Bowel Disease AU - B. Eksteen AU - J. Heatherington AU - J. Oshiomogo AU - R. Panaccione AU - G. Kaplan AU - S. Ghosh PY - 2016 JO - Journal of Hepatology DO - 10.1016/s0168-8278(16)01707-4 UR - https://doi.org/10.1016/s0168-8278(16)01707-4 ER -
APA
Eksteen, B., Heatherington, J., Oshiomogo, J., Panaccione, R., Kaplan, G., & Ghosh, S. (2016). RETRACTED: PS 124 - Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (Psc) in Individuals with Inflammatory Bowel Disease. Journal of Hepatology. https://doi.org/10.1016/s0168-8278(16)01707-4
Source records
- crossref · retrieved 2026-09-26T02:11:38.148Z